JP2018012698A5 - - Google Patents

Download PDF

Info

Publication number
JP2018012698A5
JP2018012698A5 JP2017145036A JP2017145036A JP2018012698A5 JP 2018012698 A5 JP2018012698 A5 JP 2018012698A5 JP 2017145036 A JP2017145036 A JP 2017145036A JP 2017145036 A JP2017145036 A JP 2017145036A JP 2018012698 A5 JP2018012698 A5 JP 2018012698A5
Authority
JP
Japan
Prior art keywords
methods
novel articles
manufacture substantially
manufacture
articles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017145036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018012698A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018012698A publication Critical patent/JP2018012698A/ja
Publication of JP2018012698A5 publication Critical patent/JP2018012698A5/ja
Pending legal-status Critical Current

Links

JP2017145036A 2008-08-06 2017-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤 Pending JP2018012698A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8668708P 2008-08-06 2008-08-06
US61/086,687 2008-08-06
US15103609P 2009-02-09 2009-02-09
US61/151,036 2009-02-09
US17308809P 2009-04-27 2009-04-27
US61/173,088 2009-04-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015093417A Division JP2015157843A (ja) 2008-08-06 2015-04-30 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤

Publications (2)

Publication Number Publication Date
JP2018012698A JP2018012698A (ja) 2018-01-25
JP2018012698A5 true JP2018012698A5 (cg-RX-API-DMAC10.html) 2018-09-06

Family

ID=41129519

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011522113A Active JP5984389B2 (ja) 2008-08-06 2009-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤
JP2015093417A Pending JP2015157843A (ja) 2008-08-06 2015-04-30 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤
JP2017145036A Pending JP2018012698A (ja) 2008-08-06 2017-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011522113A Active JP5984389B2 (ja) 2008-08-06 2009-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤
JP2015093417A Pending JP2015157843A (ja) 2008-08-06 2015-04-30 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤

Country Status (31)

Country Link
US (7) US8012976B2 (cg-RX-API-DMAC10.html)
EP (3) EP3241832A1 (cg-RX-API-DMAC10.html)
JP (3) JP5984389B2 (cg-RX-API-DMAC10.html)
KR (1) KR101846029B1 (cg-RX-API-DMAC10.html)
CN (3) CN102171214B (cg-RX-API-DMAC10.html)
AR (1) AR072970A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009279944B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0917119B1 (cg-RX-API-DMAC10.html)
CA (1) CA2732797C (cg-RX-API-DMAC10.html)
CY (3) CY1115022T1 (cg-RX-API-DMAC10.html)
DK (2) DK2767537T3 (cg-RX-API-DMAC10.html)
ES (2) ES2466565T3 (cg-RX-API-DMAC10.html)
FR (1) FR19C1071I2 (cg-RX-API-DMAC10.html)
GB (1) GB2462361A (cg-RX-API-DMAC10.html)
HR (1) HRP20170982T1 (cg-RX-API-DMAC10.html)
HU (2) HUE035295T2 (cg-RX-API-DMAC10.html)
IL (1) IL211070A (cg-RX-API-DMAC10.html)
LT (2) LT2767537T (cg-RX-API-DMAC10.html)
LU (1) LUC00140I2 (cg-RX-API-DMAC10.html)
MX (1) MX2011001328A (cg-RX-API-DMAC10.html)
NL (1) NL301021I2 (cg-RX-API-DMAC10.html)
NO (1) NO2019042I1 (cg-RX-API-DMAC10.html)
NZ (1) NZ591166A (cg-RX-API-DMAC10.html)
PL (2) PL2326650T3 (cg-RX-API-DMAC10.html)
PT (2) PT2767537T (cg-RX-API-DMAC10.html)
SG (2) SG10201809895YA (cg-RX-API-DMAC10.html)
SI (2) SI2326650T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201700312T1 (cg-RX-API-DMAC10.html)
TW (2) TW201422617A (cg-RX-API-DMAC10.html)
WO (1) WO2010017055A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201100897B (cg-RX-API-DMAC10.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171214B (zh) 2008-08-06 2015-06-24 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
CN106518856B (zh) 2008-12-19 2020-04-28 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
CN106943406A (zh) * 2010-02-03 2017-07-14 麦迪韦逊科技有限公司 用于pten基因缺失相关疾病的治疗的聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
JP5735988B2 (ja) * 2010-02-08 2015-06-17 ビオマリン プハルマセウトイカル インコーポレイテッド ジヒドロピリドフタラジノン誘導体を合成する方法
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
SG185524A1 (en) 2010-05-12 2012-12-28 Vertex Pharma Compounds useful as inhibitors of atr kinase
SG10201710578TA (en) 2010-10-21 2018-02-27 Medivation Technologies Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012166151A1 (en) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
EP3733185B1 (en) 2011-09-30 2022-12-07 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
MX2014008071A (es) * 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
CN103703004B (zh) 2011-12-31 2016-06-29 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
AU2013209394A1 (en) 2012-01-20 2014-08-28 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
EP2833973B1 (en) 2012-04-05 2017-09-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
WO2014073447A1 (ja) 2012-11-08 2014-05-15 日本化薬株式会社 カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
CN105916846A (zh) * 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 用于合成经保护的n-烷基三唑甲醛的三唑中间体
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
DK3157566T3 (da) 2014-06-17 2019-07-22 Vertex Pharma Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
BR112017001977A2 (pt) * 2014-07-31 2017-11-21 Medivation Technologies Inc sal coformador, método de preparação de um sal coformador e composto
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
MX395066B (es) 2015-09-30 2025-03-24 Vertex Pharma Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr).
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
CN110087730B (zh) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN108210461A (zh) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 一种Talazoparib药物组合物及其应用
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
CN107556312B (zh) * 2016-12-29 2020-04-10 广州丹康医药生物有限公司 具有parp抑制活性的新型稠环化合物、其制备方法和用途
CN107573341B (zh) * 2016-12-29 2020-08-14 广州丹康医药生物有限公司 作为parp抑制剂的新型稠环化合物、其制备方法和应用
TW201840564A (zh) 2017-02-28 2018-11-16 英屬開曼群島商百濟神州有限公司 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途
CN110650961B (zh) * 2017-05-08 2022-09-27 广州丹康医药生物有限公司 Parp抑制剂、其药物组合物、制备方法和应用
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
AU2018347331A1 (en) 2017-10-13 2020-04-09 Merck Patent Gmbh Combination of a PARP inhibitor and a PD-1 axis binding antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN108341792B (zh) * 2018-04-28 2021-09-17 苏州莱克施德药业有限公司 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN113454080B (zh) 2018-10-30 2025-10-28 修复治疗公司 化合物、药物组合物和制备化合物的方法以及其使用方法
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
WO2020229595A1 (en) 2019-05-14 2020-11-19 Molecular Targeted Radiopharmaceuticals Holding Gmbh (Mtr) Quinazoline-2,4-dione derivatives as parp inhibitors
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
CA3201467A1 (en) 2020-11-13 2022-05-19 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
JP2023551968A (ja) 2020-12-07 2023-12-13 ファイザー・インク タラゾパリブでの処置に対して感受性のある腫瘍を同定する方法およびその処置方法
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2024510666A (ja) 2021-03-24 2024-03-08 ファイザー・インク Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ
AU2022253474A1 (en) 2021-04-08 2023-11-16 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
EP4089093A1 (en) * 2021-05-12 2022-11-16 Eberhard Karls Universität Tübingen Medizinische Fakultät Radiosynthesis of [18f] talazoparib
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
AU2023279251A1 (en) 2022-06-01 2024-12-05 Glaxosmithkline Intellectual Property (No. 4) Ltd. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
US20250346599A1 (en) * 2022-06-08 2025-11-13 Valo Health, Inc. Tricyclic phthalazinone parp inhibitors and methods of use
CN115572218B (zh) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN116283924B (zh) * 2023-01-16 2024-07-26 四川效佳科技有限公司 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106631A (en) * 1870-08-23 Improvement in seed-planter
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd 2−キノロン誘導体
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
PT705903E (pt) 1994-08-12 2001-11-30 Myriad Genetics Inc Mutacoes no gene de susceptibilidade para o cancro da mama e do ovario ligado a 17q
CA2196795C (en) 1994-08-12 2001-04-03 Mark H. Skolnick Method for diagnosing a predisposition for breast and ovarian cancer
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
EP1077946A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) * 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2003211381B9 (en) 2002-02-19 2009-07-30 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2004043959A1 (ja) 2002-11-12 2004-05-27 Mochida Pharmaceutical Co., Ltd. 新規parp阻害剤
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
EP1633362B1 (en) 2003-05-28 2012-09-26 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
CN1918137B (zh) 2004-02-18 2012-08-01 阿斯利康(瑞典)有限公司 四唑化合物及其作为代谢型谷氨酸受体拮抗剂的应用
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
US20110027226A1 (en) 2007-08-22 2011-02-03 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5)
JP5439380B2 (ja) * 2007-10-03 2014-03-12 エーザイ インク. Parp阻害化合物、組成物及び使用方法
JP2011511078A (ja) 2008-02-06 2011-04-07 レアド トヘラペウトイクス,インコーポレーテッド ポリ(adpリボース)ポリメラーゼ(parp)のベンズオキサゾールカルボキサミド阻害剤
CN102171214B (zh) 2008-08-06 2015-06-24 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
CA2735560A1 (en) 2008-08-12 2010-02-18 Boehringer Ingelheim International Gmbh Process for preparing cycloalkyl-substituted piperazine compounds
CN106943406A (zh) 2010-02-03 2017-07-14 麦迪韦逊科技有限公司 用于pten基因缺失相关疾病的治疗的聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
JP5735988B2 (ja) 2010-02-08 2015-06-17 ビオマリン プハルマセウトイカル インコーポレイテッド ジヒドロピリドフタラジノン誘導体を合成する方法
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
SG10201710578TA (en) 2010-10-21 2018-02-27 Medivation Technologies Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
CN105916846A (zh) 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 用于合成经保护的n-烷基三唑甲醛的三唑中间体
BR112017001977A2 (pt) 2014-07-31 2017-11-21 Medivation Technologies Inc sal coformador, método de preparação de um sal coformador e composto

Similar Documents

Publication Publication Date Title
JP2018012698A5 (cg-RX-API-DMAC10.html)
JP2018100276A5 (cg-RX-API-DMAC10.html)
HUE054917T2 (hu) Gombafonalas bioszõnyegek, ezek elõállítási módszerei és felhasználási módjai
LT3204413T (lt) Nešiklio ir antikūno kompozicija, ir jos gamybos bei naudojimo būdai
GB2564343B (en) Composites, methods of manufacture thereof, and articles containing the composites
TWD173653S (zh) 輪圈
IL262432B (en) Modified nanocrystaline cellulose materials and formulations and products made therefrom
JP2014098143A5 (cg-RX-API-DMAC10.html)
EP3433283C0 (en) Gellan gum hydrogels, preparation, processes and related uses
JP2016028081A5 (cg-RX-API-DMAC10.html)
EP3516974A4 (en) GLOVE, DIP MOLDING COMPOSITION AND METHOD OF MANUFACTURING GLOVE
JP2018533683A5 (cg-RX-API-DMAC10.html)
JP2017137500A5 (cg-RX-API-DMAC10.html)
WO2018081502A8 (en) Synthetic bacteriophages and bacteriophage compositions
TWD173737S (zh) 肌肉鍛鍊機器
DK3408326T3 (da) Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf
JP2017537928A5 (cg-RX-API-DMAC10.html)
JP2015186128A5 (cg-RX-API-DMAC10.html)
EP3535204A4 (en) SELF-SERVICE STORAGE FACILITY, MANUFACTURING, AND METHODOLOGY
HUE046509T2 (hu) Új vegyület és eljárás
JP2017211493A5 (ja) 露光装置、および、物品の製造方法
WO2015191945A3 (en) Solid state forms of sofosbuvir
JP2016540026A5 (cg-RX-API-DMAC10.html)
JP2016540019A5 (cg-RX-API-DMAC10.html)
IL262747A (en) Anti-kv1.3 antibodies, methods for their production and use